Close
Almac
Achema middle east

American Airlines Cargo doubles cold chain flights to meet vaccine and pharma demand

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Related stories

First GLP-1 Pill for Obesity by Novo Nordisk Approved by FDA

The U.S. Food and Drug Administration – FDA on...

How High-Achievers Stay Future-Ready in Evolving Job Markets

Job markets today are transforming rapidly. In the past...

Proactive Risk Management as a Core Capability in Pharma Development

Risk management in pharma is often treated as a reactive compliance box-ticking exercise. This article argues for reframing risk as a strategic competitive advantage. It details proactive frameworks like the "Excipient Exclusion Filter," Decision Quality (DQ) matrices, and "pre-mortem" analyses that allow development teams to anticipate failure modes and engineer them out of the pipeline before they occur.
- Advertisement -

American Airlines Cargo has expanded its temperature-controlled shipping capabilities to the company’s entire mainline fleet, nearly doubling its customers’ cold chain flight options and allowing it to meet growing market demand for distributing temperature-critical cargo like vaccines and pharmaceuticals.

Fort Worth, Texas-based American launched the new service after trials where it used packaging from CSafe Global and temperature loggers from CargoSense, monitoring internal package temperatures while planes operated in a variety of climates. Those tests showed that its planes supported appropriate environments for passive, temperature-sensitive shipments, the airline said.

The expanded service is part of American’s ExpediteTC solution, which offers both active and passive shipping solutions as well as a global network of temperature-controlled facilities, including a 25,000-square-foot temperature-controlled center in Philadelphia that specializes in pharmaceuticals.

Following the rollout, American has nearly doubled its capacity for handling ExpediteTC solutions and extended the airline’s cold-chain solution network to 30 new stations, including in-demand cities like Cincinnati, Memphis, and Pittsburgh, the company said.

“When it comes to cold chain shipments, reliability is crucial for our customers,” said Roger Samways, vice president of commercial for American Airlines Cargo, said in a release. “By expanding our offering of temperature-critical shipping on all mainline flights, we are able to provide our customers with access to more than 180 markets, marking the largest cold-chain network in our history.”

The expansion follows a flurry of recent investment in the cold chain sector, such as refrigerated warehouse giant Lineage Logistics buying its own cold chain railcar fleet in January and smaller players like RLS Logistics and Burris Logistics expanding their regional networks.

 

 

Latest stories

Related stories

First GLP-1 Pill for Obesity by Novo Nordisk Approved by FDA

The U.S. Food and Drug Administration – FDA on...

How High-Achievers Stay Future-Ready in Evolving Job Markets

Job markets today are transforming rapidly. In the past...

Proactive Risk Management as a Core Capability in Pharma Development

Risk management in pharma is often treated as a reactive compliance box-ticking exercise. This article argues for reframing risk as a strategic competitive advantage. It details proactive frameworks like the "Excipient Exclusion Filter," Decision Quality (DQ) matrices, and "pre-mortem" analyses that allow development teams to anticipate failure modes and engineer them out of the pipeline before they occur.

Rethinking Pipeline Value Beyond Peak Sales Forecasts

The traditional reliance on risk-adjusted Net Present Value (rNPV) and peak sales forecasts is failing to capture the true potential of modern pharmaceutical assets, particularly platform technologies. This article introduces holistic valuation frameworks like Real Options Analysis (ROA) and the Platform VISTA model, arguing for a shift toward valuing "strategic fit," "lifecycle potential," and the intangible equity of innovation engines.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Translate »